Evidence map›Paper›PMID 37400350›Full record

ArticleNeuromuscular disorders : NMD2023

Lean tissue mass measurements by dual-energy X-ray absorptiometry and associations with strength and functional outcome measures in facioscapulohumeral muscular dystrophy.

Leo H Wang, Doris G Leung, Kathryn R Wagner, Sarah J Lowry, Michael P McDermott, Katy Eichinger, Kiley Higgs, Michaela Walker, Leann Lewis, William B Martens and 13 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuromuscular disorders : NMD, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 12 institutions in 3 countries.

Leo H WangUniversity of Washington, Department of Neurology, WA, USA. Electronic address: leowang@uw.edu.
Doris G LeungKennedy Krieger Institute, The Johns Hopkins School of Medicine, MD, USA.
Kathryn R WagnerKennedy Krieger Institute, The Johns Hopkins School of Medicine, MD, USA.
Sarah J LowrySeattle Children's Research Institute, WA, USA.
Michael P McDermottUniversity of Rochester Medical Center, Department of Biostatistics and Computational Biology, NY, USA; University of Rochester Medical Center, Department of Neurology, NY, USA.
Katy EichingerUniversity of Rochester Medical Center, Department of Neurology, NY, USA.
Kiley HiggsUniversity of Kansas Medical Center, Department of Neurology, KS, USA.
Michaela WalkerUniversity of Kansas Medical Center, Department of Neurology, KS, USA.
Leann LewisUniversity of Rochester Medical Center, Department of Biostatistics and Computational Biology, NY, USA.
William B MartensUniversity of Rochester Medical Center, Department of Biostatistics and Computational Biology, NY, USA.
Karlien MulRadboud University, Nijmegen, Netherlands.
Valeria A SansoneThe NEMO Clinical Center, Neurorehabilitation Unit, University of Milan, Department of Neurology, Milan, Italy.
Perry ShiehUniversity of California, Los Angeles, CA, USA.
Bakri ElsheikhThe Ohio State University, OH, USA.
Samantha LoRussoThe Ohio State University, OH, USA.
Russell J ButterfieldUniversity of Utah, UT, USA.
Nicholas JohnsonVirginia Commonwealth University, VA, USA.
Matthew R PrestonUniversity of Washington, Department of Neurology, WA, USA.
Carmelo MessinaGaleazzi Institute, Radiology Department, University of Milan, Italy.
Elena CarraroThe NEMO Clinical Center, Neurorehabilitation Unit, University of Milan, Department of Neurology, Milan, Italy.
Rabi TawilUniversity of Rochester Medical Center, Department of Neurology, NY, USA.
Jeff StatlandUniversity of Kansas Medical Center, Department of Neurology, KS, USA.
ReSolve Investigators of the FSHD CTRN
University of Rochester Medical Center · USUniversity of Kansas Medical Center · USKennedy Krieger Institute · USThe Ohio State University · USUniversity of Washington · USCentro Clinico Nemo · ITIstituto Ortopedico Galeazzi · ITRadboud University Nijmegen · NLUniversity of California, Los Angeles · USUniversity of Milan · ITUniversity of Utah · USVirginia Commonwealth University · US

Funding

Sleep and Circadian Dysfunction, Brain and Neurobehavioral Development in AutismP50HD103538 · NICHD · HUGO W. MOSER RES INST KENNEDY KRIEGER · PI S. Ali Fatemi, Bradley L Schlaggar · 2020 to 2026
$9.9M
Identifying the RNA Splicing and Gene Expression Changes that Cause Congenital Myotonic Dystrophy (Renewal)R01NS104010 · NINDS · VIRGINIA COMMONWEALTH UNIVERSITY · PI Nicholas Elwood Johnson · 2018 to 2026
$4.4M
Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type-1 (Renewal)R01FD006071 · FDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI Nicholas Elwood Johnson, CHARLES A THORNTON · 2017 to 2026
$3.7M
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHDU01NS101944 · NINDS · UNIVERSITY OF ROCHESTER · PI STATLAND, JEFFREY, TAWIL, RABI · 2017 to 2022
$3.2M
Development and validation of clinical outcome assessments in LGMD2AR21TR003184 · NCATS · VIRGINIA COMMONWEALTH UNIVERSITY · PI JOHNSON, NICHOLAS ELWOOD, STATLAND, JEFFREY · 2020 to 2021
$452k
ACL HHS U01DD001242FDA HHS R01 FD006071NCATS NIH HHS R21 TR003184NCBDD CDC HHS U01 DD001242NICHD NIH HHS P50 HD103538NINDS NIH HHS R01 NS104010NINDS NIH HHS U01 NS101944
6 · The paper itself

Abstract

Facioscapulohumeral muscular dystrophy (FSHD) is a slowly progressive disease of skeletal muscle. Dual energy X-ray absorptiometry (DEXA) is a widely available, cost-effective and sensitive technique for measuring whole body and regional lean tissue mass and has been used in prior clinical trials in neuromuscular diseases. The Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD (ReSolve) study is a prospective, longitudinal, observational multisite study. We obtained concurrent DEXA scans and functional outcome measurements in 185 patients with FSHD at the baseline visit. We determined the associations between lean tissue mass in the upper and lower extremities and corresponding clinical outcome measures. There were moderate correlations between upper and lower extremity lean tissue mass and their corresponding strengths and function. Lean tissue mass obtained by DEXA scan may be useful as a biomarker in future clinical trials in FSHD.

Indexed as

Muscular Dystrophy, FacioscapulohumeralAbsorptiometry, PhotonHumansMuscle, SkeletalOutcome Assessment, Health CareProspective StudiesFacioscapulohumeral muscular dystrophyImaging markersLeg strengthPatient reported outcome

Identifiers

PMID37400350
PMCPMC10527411
OpenAlexW4381487528

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.